Ozempic Alternatives in 2026: What Actually Works and How to Access Them

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Clinical research cited here used FDA-approved pharmaceutical formulations; results with compounded versions may differ. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or changing any medication. Care at Prescriva is delivered by independently licensed providers, not by Prescriva LLC, doing business as Prescriva, which is a management services organization.*

---

Ozempic costs over $900 per month without insurance. That figure alone explains why millions of Americans are looking for alternatives.

The good news is that the GLP-1 medication landscape has expanded considerably since Ozempic became a household name. In 2026, people who want access to this class of medication have more options than at any point in the past. Some are more affordable. Some are newer and in several cases more effective. Some are taken differently.

This guide covers the main Ozempic alternatives available in 2026, what the research says about each one, and what to consider when deciding which path makes sense for your situation.

---

Why People Look for Ozempic Alternatives

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg, weekly injection) is approved by the FDA for type 2 diabetes management, not for weight loss in adults without diabetes. Wegovy, a higher-dose version of the same molecule (2.4 mg), is approved for chronic weight management.

Despite the distinction, Ozempic became the culturally dominant name for GLP-1 weight loss medications, and demand surged far beyond what the manufacturer could supply. Several patterns drove people to look for alternatives:

Cost without insurance. Without coverage, Wegovy and Ozempic typically cost $900 to $1,300 per month. Most insurance plans do not cover weight management drugs, even when coverage exists for diabetes.

Supply shortages. From 2022 through late 2024, both Ozempic and Wegovy faced repeated supply disruptions. The FDA formally declared a shortage, which opened the door for licensed compounding pharmacies to produce alternatives.

Availability through telehealth. As demand grew, telehealth platforms began offering FDA-approved and compounded alternatives with online prescriptions and home delivery, making the category accessible without specialist referrals.

Better options emerging. Newer medications in the same class, particularly tirzepatide, have shown greater weight loss in clinical trials, leading some patients and providers to consider alternatives not because Ozempic is inadequate, but because there may be more effective options.

---

What Makes a Good Ozempic Alternative?

Before comparing options, it helps to define what you are actually comparing. Ozempic's mechanism is semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone the gut releases after eating. It signals fullness to the brain, slows gastric emptying, and reduces appetite.

A meaningful Ozempic alternative should:

• Engage the same or related biological pathways
• Have clinical evidence supporting weight loss outcomes
• Be accessible through a legitimate medical channel
• Include prescriber oversight and monitoring

Some alternatives are FDA-approved medications. Others are compounded versions of approved molecules, produced by licensed 503A compounding pharmacies. These are not interchangeable categories, and the differences matter for how you think about each option.

---

Option 1: Compounded Semaglutide

Closest match to Ozempic. Meaningfully lower cost.

Compounded semaglutide is the most direct alternative for most people comparing options. It uses the same active molecule as Ozempic and Wegovy, semaglutide, but is produced by 503A-licensed compounding pharmacies rather than manufactured by Novo Nordisk.

Compounded medications are not FDA-approved. They are not equivalent to branded medications and have not gone through the same approval process. That distinction matters.

What compounded semaglutide offers is access. When Ozempic and Wegovy were on the FDA shortage list, 503A pharmacies were legally permitted to compound semaglutide. As of mid-2026, the FDA's shortage determination for branded semaglutide has evolved, and access to compounded versions depends on the specific regulatory status at the time of your prescription. A licensed provider can clarify what is currently available.

The clinical evidence context. The research supporting semaglutide's effectiveness was conducted using FDA-approved formulations. The STEP 1 trial, published in the New England Journal of Medicine, found that adults with obesity who received once-weekly semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks, compared with 2.4 percent with placebo. [1] That evidence base applies to the pharmaceutical-grade formulation. Individual results with compounded preparations may differ.

Cost. Compounded semaglutide programs typically range from $150 to $300 per month through telehealth platforms, depending on dosage and program structure.

How to access it. Telehealth programs like Prescriva connect you with a licensed provider who reviews your health history, determines eligibility, and can prescribe compounded semaglutide if appropriate. The medication is dispensed by a licensed 503A pharmacy and shipped directly to you.

---

Option 2: Tirzepatide (Mounjaro or Zepbound)

Newer dual-action medication. Strongest weight loss data in the class.

Tirzepatide is the most significant GLP-1 class development since semaglutide. Where semaglutide activates only the GLP-1 receptor, tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both are gut hormones involved in insulin secretion and appetite regulation.

The dual mechanism appears to produce stronger weight loss outcomes. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that participants receiving tirzepatide 15 mg lost an average of 20.9 percent of body weight at 72 weeks. [2] That is meaningfully higher than the outcomes from semaglutide trials, though direct head-to-head comparisons have limitations.

FDA approval status. Tirzepatide is FDA-approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound.

Compounded tirzepatide follows similar rules to compounded semaglutide. Licensed 503A pharmacies can compound tirzepatide when specific conditions are met. Access depends on current regulatory status.

Side effect profile. Tirzepatide shares a similar gastrointestinal side effect profile with semaglutide: nausea, constipation, and diarrhea are the most common, particularly during dose increases. Most people experience these as manageable and temporary.

Cost. Brand-name Zepbound without insurance costs approximately $900 to $1,100 per month. Compounded tirzepatide programs are typically in the $200 to $350 range.

---

Option 3: Oral Semaglutide (Rybelsus)

Same molecule as Ozempic, no injection required.

For people who prefer to avoid weekly injections, Rybelsus is an FDA-approved oral formulation of semaglutide. It is approved for type 2 diabetes management and is taken as a daily tablet, not a weekly injection.

The weight management evidence for oral semaglutide is meaningful, but the dosing is different from injectable semaglutide. In the PIONEER trials, oral semaglutide produced weight loss outcomes, though somewhat less than the injectable 2.4 mg formulation used for weight management.

Key limitation. Oral semaglutide must be taken in very specific conditions: fasting, with no more than 4 oz of water, at least 30 minutes before eating or other medications. Absorption is lower and more variable than injectable semaglutide. Adherence to the fasting requirement affects effectiveness.

Access and cost. Rybelsus requires a prescription and is available through standard pharmacies. Without insurance, cost ranges from $850 to $1,100 per month.

---

Option 4: Liraglutide (Saxenda)

An older GLP-1 approved for weight management. Daily injection.

Liraglutide was the first GLP-1 receptor agonist FDA-approved specifically for weight management. It is marketed as Saxenda at the 3 mg dose for chronic weight management and as Victoza for type 2 diabetes.

The SCALE Obesity and Prediabetes trial found that liraglutide 3 mg produced an average weight loss of 8.4 percent over 56 weeks in adults with overweight or obesity, compared with 2.8 percent with placebo. [3] That is a meaningful result, though smaller than what the newer weekly injections produce.

Liraglutide requires a daily injection rather than a weekly one, which many people find less convenient. Supply and cost have also been affected by the broader GLP-1 market dynamics.

When it might be relevant. Liraglutide may be an option when newer medications are unavailable, when insurance specifically covers it, or when a prescriber recommends it based on an individual clinical situation. It is not generally the first recommendation in 2026 given the performance advantages of semaglutide and tirzepatide.

---

Option 5: Orforglipron (Foundayo)

Oral GLP-1, no injection, no special timing requirements.

Orforglipron, marketed as Foundayo, is the newest entrant to the GLP-1 class to receive FDA approval. Unlike Rybelsus, which requires a strict fasting protocol, orforglipron can be taken with food and without special timing restrictions.

Phase 3 clinical data published in early 2025 showed weight loss of approximately 16 percent at 36 weeks at the highest studied dose. The oral, non-peptide structure of orforglipron means it does not require the precise absorption conditions of oral semaglutide.

Orforglipron is a reasonable option for people who specifically want to avoid injections and want a more convenient oral regimen than Rybelsus allows. It is a new medication, and long-term data are still accumulating compared to the deeper evidence base behind semaglutide and tirzepatide.

---

Option 6: Lifestyle Programs Alone

Not equivalent to medication, but a legitimate starting point for some.

GLP-1 medications produce significantly greater weight loss than lifestyle interventions alone. However, some people are not candidates for medication, or prefer to start with behavioral approaches while exploring medication options.

The clinical data are clear: for people with significant obesity or weight-related health conditions, GLP-1 medications combined with lifestyle changes consistently outperform lifestyle changes alone. The STEP 1 trial included lifestyle counseling in both arms, and the medication-plus-lifestyle group lost 14.9 percent of body weight versus 2.4 percent in the placebo-plus-lifestyle arm. [1]

Lifestyle programs are not an Ozempic alternative in the same mechanistic sense. They are worth mentioning here because some people begin researching alternatives when cost or access barriers make medication unavailable, and a structured lifestyle program may be a useful bridge.

---

Long-Term Effectiveness: What the Research Shows

One consistent finding across GLP-1 research is that sustained use produces better outcomes than short-term treatment.

The STEP 5 trial followed adults on semaglutide 2.4 mg for two years and found continued weight loss through 104 weeks, with an average reduction of 15.2 percent of body weight at two years. [4] The weight loss trajectory continued well past the first year for many participants.

This has practical implications. GLP-1 medications are most effective when treated as long-term therapy, not a short-term intervention. People who stop treatment typically regain weight. Any alternative you consider should be viewed through the lens of what is sustainable for you over months and years, not just what produces the fastest early result.

---

How to Choose the Right Alternative

There is no single best option. The right choice depends on several factors a prescriber should help you evaluate:

Your health history. Certain conditions affect which medications are appropriate. Thyroid cancer history, pancreatitis history, and kidney function all factor into GLP-1 prescribing decisions. This is why prescriber involvement matters, not just access to a medication.

Injection preference. If injections are a genuine barrier, oral options including Rybelsus and orforglipron exist. If a weekly injection is manageable, compounded semaglutide or tirzepatide offer strong evidence and lower cost.

Budget. Compounded GLP-1 programs from telehealth providers are typically $150 to $350 per month, compared with $900 to $1,300 for brand-name alternatives without insurance. If insurance covers branded medications, that changes the calculation.

Weight loss goals. The clinical evidence suggests tirzepatide produces greater average weight loss than semaglutide. For people with significant weight to lose, this difference may factor into the decision.

Regulatory and access status. The landscape for compounded medications changes. A licensed provider can tell you what is currently available and legally accessible in your state.

---

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide uses the same active molecule but is produced by a licensed compounding pharmacy rather than the pharmaceutical manufacturer. It has not gone through the FDA's drug approval process and is not equivalent to an FDA-approved product. The clinical research supporting semaglutide's effectiveness was conducted using FDA-approved formulations.

Can I switch from Ozempic to compounded semaglutide?

This is a decision to make with your prescribing provider, not on your own. If a switch makes sense for your situation, your provider can guide the transition and adjust dosing appropriately.

Is tirzepatide better than semaglutide?

Clinical trial data show tirzepatide produced greater average weight loss at the highest doses in the SURMOUNT-1 trial compared with what semaglutide achieved in the STEP 1 trial. Direct head-to-head trials exist, and outcomes vary based on individual factors. One medication is not universally better for every person.

Do I need a prescription for these alternatives?

Yes. All GLP-1 medications, including compounded versions, require a valid prescription from a licensed healthcare provider. Programs that offer these medications without a proper clinical consultation and prescription are not operating legally.

What if my insurance covers Ozempic but not Wegovy?

Ozempic is approved for type 2 diabetes, not weight management in people without diabetes. Coverage typically follows the FDA indication. Wegovy is the weight management version, and coverage policies differ. Talk to your provider about what your insurance covers and what alternatives exist if coverage is limited.

---

The Bottom Line

The days of Ozempic being the only option are over. In 2026, the GLP-1 medication category includes weekly injectables, daily injectables, oral options with strict timing requirements, and oral options without them. Compounded versions have expanded access at lower price points for people who would otherwise be priced out.

None of these options are interchangeable, and none should be started without a proper clinical evaluation. The right alternative depends on your health history, your goals, what is currently available, and what you will actually stay on long enough to see results.

A licensed telehealth provider can walk you through what is currently available, whether you are a candidate, and what to expect.

*Ready to explore your options? Check your eligibility with Prescriva to connect with a licensed provider and find out which GLP-1 program may be right for you.*

---

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine.* 2021;384(11):989-1002. PMID: 33567185.

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine.* 2022;387(3):205-216. PMID: 35658024.

1. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *New England Journal of Medicine.* 2015;373(1):11-22. PMID: 26132939.

1. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nature Medicine.* 2022;28(10):2083-2091. PMID: 36216945.